Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This medication helps improve lung function and oxygenation.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. Curosurf works by replacing the missing surfactant, allowing the lungs to function more effectively. It is administered directly into the lungs via endotracheal tube, providing immediate relief and support for breathing.

Curosurf helps to reduce the surface tension in the lungs, which allows the air sacs to stay open and function properly. This can lead to improved oxygenation and reduced need for mechanical ventilation. The effects are typically observed shortly after administration, providing rapid relief for infants suffering from respiratory distress.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is important to follow proper handling and storage guidelines to maintain the efficacy of the medication. Always consult a healthcare provider for specific instructions and precautions related to the use of Curosurf.

Curosurf is generally well-tolerated, but interactions with other medications should be considered. It is important to inform your healthcare provider about any other medications or treatments the infant is receiving. Always follow the advice of a healthcare professional regarding the use of Curosurf in combination with other therapies.